Alpha Cognition Inc. ACOG
- Market cap
- $186.6M
- P/E
- 0.0×
Follow ACOG
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 17.35 | 26.08 | 30.04 | — | — | — | — | — | 4.66 | 3.75 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 26.51 | 28.43 | 30.50 | — | — | — | — | — | 7.00 | 11.54 |
High Price
|
|||
| — | — | — | — | — | — | — | — | 57 | 71 |
Employees
|
|||
| — | — | — | — | — | — | — | — | 0 | 0 |
Revenue/Emp
|
|||
| — | — | — | — | — | — | — | — | — | 10 |
Revenue
|
|||
| — | — | — | — | — | — | — | — | — | 81.26% |
Gross Margin
|
|||
| — | — | — | (7) | (6) | (20) | (12) | (14) | (15) | (21) |
EBT
|
|||
| — | — | — | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (202.24%) |
EBT Margin
|
|||
| — | — | — | (7) | (6) | (20) | (12) | (14) | (15) | (21) |
Net Income
|
|||
| — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Depreciation
|
|||
| — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.58 |
Revenue/Sh
|
|||
| — | — | — | (5.25) | (3.37) | (9.25) | (4.50) | (3.75) | (2.02) | (1.17) |
Earnings/Sh
|
|||
| — | — | — | (2.03) | (3.17) | (4.63) | (3.40) | (2.45) | (1.07) | (1.15) |
Cash Flow/Sh
|
|||
| — | — | — | 0.00 | (0.01) | (0.03) | 0.00 | 0.00 | 0.00 | (0.02) |
Capex/Sh
|
|||
| — | — | — | (2.03) | (3.17) | (4.66) | (3.40) | (2.45) | (1.07) | (1.17) |
Free CF/Sh
|
|||
| — | — | — | 4.17 | 0.01 | 4.23 | (0.49) | (1.31) | 5.39 | 3.54 |
Book Value/Sh
|
|||
| — | — | — | 1 | 2 | 2 | 3 | 4 | 7 | 18 |
Shares
|
|||
| — | — | — | — | — | — | — | — | — | 0.00 |
PE Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 11.24 |
PS Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 1.84 |
PB Ratio
|
|||
| — | — | — | — | — | — | — | — | — | 4.87 |
EV/Sales
|
|||
| — | — | — | — | — | — | — | — | — | (2.40) |
EV/FCF
|
|||
| — | — | — | (3) | (5) | (10) | (9) | (9) | (8) | (20) |
Op' Cash Flow
|
|||
| — | — | — | — | 0 | 0 | 0 | — | 0 | 0 |
Capex
|
|||
| — | — | — | (3) | (5) | (10) | (9) | (9) | (8) | (21) |
FCF
|
|||
| — | — | — | 5 | 4 | 10 | (2) | (1) | 47 | 70 |
Working Cap'
|
|||
| — | — | — | 1 | 3 | — | — | — | — | — |
Total Debt
|
|||
| — | — | — | (5) | (3) | (11) | (2) | (1) | (49) | (66) |
Net Debt
|
|||
| — | — | — | 5 | 0 | 9 | (1) | (5) | 39 | 63 |
Sh' Equity
|
|||
| — | — | — | 0.00% | (78.00%) | (183.38%) | (153.05%) | (509.46%) | (55.61%) | (31.69%) |
ROA
|
|||
| — | — | — | (685.00%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
ROIC
|
|||
| — | — | — | 0.00% | (219.92%) | (432.14%) | (314.28%) | 456.96% | (86.00%) | (40.68%) |
ROE
|
|||
Alpha Cognition Inc. peers in Biotechnology
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ALXO ALX Oncology Holdings Inc. | $187.4M | 0.0× | Compare |
| PEPG PepGen, Inc. | $185.6M | 0.0× | Compare |
| MSLE Satellos Bioscience Inc. | $184.8M | 0.0× | Compare |
| IPHA Innate Pharma S.A. Sponsored ADR | $188.8M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| ANTX AN2 Therapeutics, Inc. | $184.5M | 0.0× | Compare |
| CHRS Coherus Oncology, Inc. | $183.9M | 0.0× | Compare |
| CNTN Canton Strategic Holdings, Inc. | $191.2M | 13.7× | Compare |
| MDWD MediWound Ltd. | $178.6M | 0.0× | Compare |
Alpha Cognition Inc. (ACOG) key facts
- Alpha Cognition Inc. (ACOG) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- Alpha Cognition Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.2 million.
- As of September 25, 2026, ACOG traded at $8.47, a market capitalization of $186.6 million.
- Return on equity was −40.7% and debt-to-equity 0.00.
Alpha Cognition Inc. (ACOG) Latest News
17 Aug
Alpha Cognition (ACOG) stock fair value rises due to analyst optimism on Zunveyl. Analyst optimism on Zunveyl directly lifts ACOG fair value and near-term sentiment.
14 Aug
Alpha Cognition Inc. (ACOG) held its Q2 2026 earnings call to review financial results, operational updates, and forward outlook. Quarterly earnings calls deliver financial metrics and strategy details that can shift near-term investor sentiment without guaranteed long-term trajectory changes.
13 Aug
Alpha Cognition Inc. (ACOG) held its Q2 2026 earnings call discussing financial results and company outlook. Earnings call delivers financial results and guidance that can significantly shift investor sentiment and stock trajectory.
Alpha Cognition Inc. (ACOG) shared Q2 financial results, operational updates, and forward guidance during its earnings call. Quarterly earnings updates and guidance influence near-term financial outlook and investor sentiment without major strategic shifts.
Alpha Cognition Inc. (ACOG) posted a Q2 loss while exceeding revenue estimates. Q2 loss paired with revenue beat creates moderate near-term effects on valuation and sentiment.
Alpha Cognition Inc. (ACOG) released second quarter 2026 financial results and an operational update. Quarterly results and operational updates supply performance data that can shift near-term investor views without fundamentally redefining long-term trajectory.
29 Jul
Alpha Cognition Inc. (ACOG) received a European patent covering ZUNVEYL® for treatment of mild-to-moderate Alzheimer’s disease. European patent grant strengthens intellectual property protection for ZUNVEYL® and supports potential market expansion.
11 Jul
Analysts lowered Alpha Cognition (ACOG) stock fair value while assessing Zunveyl's market persistence. Analyst fair value reduction tied to Zunveyl persistence signals moderate valuation and sentiment effects.
16 Jun
Alpha Cognition Inc. enrolled the first patient in its RESOLVE Phase 4 study evaluating ZUNVEYL for mild to moderate Alzheimer’s Disease. Phase 4 study start signals continued ZUNVEYL development with moderate potential to support future adoption and market positioning.
9 Jun
Alpha Cognition Inc. reported positive top-line results from the BEACON real-world study of ZUNVEYL in Alzheimer’s disease. Positive BEACON study outcomes for ZUNVEYL strengthen Alpha Cognition's position in the Alzheimer's market.
17 May
Alpha Cognition Inc. reported results with analysts assigning a US$16.00 price target for ACOG shares. Analyst US$16 price target after reporting may moderately lift ACOG investor sentiment.
15 May
Alpha Cognition Inc. (ACOG) Q1 2026 earnings call outlined financial results, operational updates, and forward guidance for investors. Q1 2026 earnings provide performance metrics and outlook that moderately shape near-term stock sentiment.
14 May
Alpha Cognition Inc. (ACOG) released Q1 earnings call highlights covering financial results, operational updates, and forward guidance. Q1 earnings call highlights impact financial performance and investor sentiment but are tempered by market expectations.
Alpha Cognition Inc. (ACOG) reported a Q1 loss but topped revenue estimates. Q1 loss despite revenue beat affects financial performance and market sentiment moderately.
Alpha Cognition Inc. (ACOG) reported first quarter 2026 financial results and provided an operational update. Quarterly financial results and operational updates affect financial performance and investor sentiment but are routine disclosures.
7 May
Alpha Cognition Inc. (ACOG) is forecasted to surpass Q1 earnings estimates, driven by strong Z-score trends, historical beats, and positive EPS growth; key metrics to watch include revenue and pipeline updates ahead of release. Anticipated Q1 earnings beat targets financial performance and investor sentiment but remains limited to quarterly results.
19 Apr
Alpha Cognition Inc. (NASDAQ:ACOG) outlines its strategic path to profitability amid ongoing operations and market positioning. Mapping a path to profitability represents a major strategic shift likely to significantly enhance ACOG's financial trajectory and investor confidence.
1 Apr
Alpha Cognition Inc. (ACOG) receives issued U.S. patent for ALPHA-1062, targeting treatment of Traumatic Brain Injury. U.S. patent issuance for ALPHA-1062 bolsters ACOG's intellectual property protection and commercialization potential for TBI treatment.
Alpha Cognition Inc. (ACOG) released its Q4 2025 earnings call transcript detailing quarterly financial results, operational updates, and forward-looking guidance. Q4 earnings transcript discloses financial performance and strategic outlook capable of significantly swaying investor sentiment and stock trajectory.
27 Mar
Alpha Cognition Inc. (ACOG) released Q4 2025 earnings call summary, covering financial results, operational updates, and forward guidance for the quarter. Q4 earnings call summaries disclose financial metrics, guidance, and strategies that significantly sway investor sentiment and stock trajectory.
26 Mar
Alpha Cognition Inc. (ACOG) Q4 earnings call highlights financial results, operational updates, and forward guidance. Q4 earnings highlights reveal financial performance and strategic direction, significantly impacting ACOG's stock trajectory and investor sentiment.
Alpha Cognition Inc. (ACOG) reported fiscal 2025 financial results and provided an operational update. Annual financial results and operational updates signal key progress on core operations, potentially shifting investor sentiment and stock trajectory.
15 Mar
Payments stock Alpha Cognition Inc. (ACOG) plunges 30% despite $4 billion revenue, drawing $6 million investor bet. $4 billion revenue fundamentally transforms ACOG's competitive position and long-term prospects despite stock drop.
10 Mar
Alpha Cognition to present new clinical data on ZUNVEYL (Benzgalantamine) at multiple upcoming Alzheimer’s Association International Conferences. Presenting new clinical data at major Alzheimer’s conferences boosts visibility, credibility, and investor sentiment for ZUNVEYL in a competitive market.
25 Feb
Alpha Cognition Inc. (ACOG) announced the enrollment of the first patient in the BEACON real-world effectiveness study. First patient enrollment advances real-world evidence generation for Alpha Cognition's cognitive therapeutics, potentially influencing clinical validation and investor sentiment.
18 Feb
Alpha Cognition Inc. (ACOG) announces the issuance of an additional U.S. patent covering dosing regimens for its product ZUNVEYL®. Additional U.S. patent for ZUNVEYL® dosing regimens strengthens ACOG's IP portfolio, protecting product exclusivity and boosting long-term market position.
16 Feb
Several insiders invested in Alpha Cognition Inc. (ACOG), signaling positive news ahead. Insider investments indicate strong internal confidence, likely boosting investor sentiment and stock performance significantly.
7 Jan
Alpha Cognition Inc. provided a corporate update outlining its strategic priorities for 2026 and plans for commercial execution in 2025. The company emphasized its focus on advancing its product pipeline and enhancing market presence, aiming to drive growth and improve financial performance. Key initiatives include strengthening partnerships and expanding distribution channels to maximize reach and impact in the cognitive health sector. The outlined strategic priorities and commercial execution plans are expected to significantly influence Alpha Cognition's market positioning and future performance.
6 Jan
Hedge funds hold 20% of Alpha Cognition Inc. (NASDAQ: ACOG) shares, while individual investors control 53% of the company. This distribution indicates a significant level of retail investor engagement in ACOG, potentially influencing the company's governance and strategic direction. The ownership distribution may affect market sentiment and investor dynamics, but its overall impact on the company's trajectory is expected to be limited.
5 Dec
Alpha Cognition Inc. (ACOG) has been underperforming compared to other medical stocks this year, raising questions about its market position and future growth potential. Analysts are examining the factors contributing to this lag, including competition and market dynamics. Investors are advised to consider these elements when evaluating ACOG's stock performance and potential recovery. ACOG's underperformance relative to peers suggests moderate concerns that could affect its market position and investor sentiment.